Company profile
Ipsen
IPN · Euronext Paris (Epizyme, Inc. was fully acquired by Ipsen via tender offer completed 2022 (Ipsen press releases, businesswire.com) and is no longer independently traded (former ticker EPZM delisted). Attributed to acquirer Ipsen (public, Euronext Paris: IPN), which is not yet on the roster and should be created as a new company row, per this project's established acquirer-reattribution precedent (e.g. Harpoon Therapeutics -> Merck & Co.). Sources: https://clinicaltrials.gov/study/NCT05121103 ; https://api.gleif.org/api/v1/lei-records/549300TNFWF88O4U4605 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://api.gleif.org/api/v1/lei-records/254900ESD9GZFY66OR92 ; https://api.gleif.org/api/v1/lei-records/549300NIGKDV9203Q946 Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for Ipsen are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Mesdopetam (IRL790)No recent activity | Phase 3 | D3Small molecule | Parkinson's Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.